CSP
GILD icon

Cary Street Partners’s Gilead Sciences GILD Stock Holding History

Cary Street Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Buy
12,378
+6,320
+104% +$833K 0.03% 409
2026
Q1 		$844K Sell
6,058
-829
-12% -$116K 0.02% 476
2025
Q4 		$845K Buy
6,887
+1,367
+25% +$166K 0.02% 483
2025
Q3 		$613K Sell
5,520
-684
-11% -$77.7K 0.02% 527
2025
Q2 		$688K Buy
6,204
+10
+0.2% +$1.06K 0.02% 479
2025
Q1 		$694K Sell
6,194
-153
-2% -$15.8K 0.02% 470
2024
Q4 		$586K Buy
+6,347
New +$571K 0.02% 482

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cary Street Partners's GILD Position: Q2 2026 in Review

Cary Street Partners increased its Gilead Sciences (GILD) stake by 104% in Q2 2026, buying an estimated $833K and bringing the position to 12,378 shares worth $1.56M. The position accounts for 0.03% of the portfolio, ranked #409.

Cary Street Partners first reported a position in GILD in Q4 2024 and has held it in 7 quarters since. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Cary Street Partners held 12,378 shares of Gilead Sciences worth $1.56M as of Q2 2026.
  • Cary Street Partners bought 6,320 Gilead Sciences shares in Q2 2026, an estimated $833K.
  • Gilead Sciences made up 0.03% of Cary Street Partners's portfolio in Q2 2026, its #409 holding.
  • Cary Street Partners first reported a position in Gilead Sciences in Q4 2024 and has held it in 7 quarters since.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.